Navigation Links
Leading pharmacologists to meet in Brighton
Date:12/12/2008

The latest developments in drug discovery including solutions to tackle obesity, the latest on the Northwick Park drug-trial disaster and issues surrounding drugs used in sport and the Olympics will be highlighted at a conference in Brighton next week.

The British Pharmacological Society (BPS), Europe's leading pharmacological research society, is to host its Winter Meeting in the seaside resort, attracting experts from across the world.

Running from 16 to 18 December, the three-day conference will hear the latest research tackling the global obesity problem.

Other researchers will present their work on the safety of drugs, particularly the new biopharmaceuticals developed in the wake of the Northwick Park drug-trial disaster in 2006 that left six volunteers fighting for their lives.

A third theme of the conference will examine the latest techniques using stem-cell therapies to tackle heart disease.

Just three presentations from the packed programme will be press released but newsworthy research to be presented at the Brighton conference includes:

  • Professor Luke O'Neill (Trinity College Dublin): 'The IL-1 receptor / Toll-like receptor super-family: 10 years of progress'
  • Professor O'Neill's talk will deal with possible new targets for drugs to treat immune and inflammatory diseases.
  • These targets are the Toll-like receptors (TLRs) and they have been identified as possible new targets to block in such diseases as rheumatoid arthritis, inflammatory bowel disease, atherosclerosis and multiple sclerosis.
  • They are also implicated in infectious diseases such as malaria and TB. TLRs have been shown to be over-active in these diseases - they go into overdrive and cause inflammation and damage.
  • There is a consensus emerging that inhibiting them might prove useful to treat these diseases, or, alternatively, if they are activated, they might boost the immune response to help generate new vaccines.
  • In his talk, Professor O'Neill will lay out the case for TLRs as excellent new targets worth exploring for these diseases where there remains a major unmet medical need.
  • He will also describe what to target his team has found proteins within the Toll-like receptor pathway that might lend themselves to therapeutic manipulation.
  • TLRs may also prove essential in the fight against malaria, as the disease has recently shown resistance to current medication (16 Dec).
  • Dr Sandra Diebold (Cancer Research UK): 'Stimulatory nucleic acids as adjuvants for tumour immunotherapty' (16 Dec)
  • Dr Stephen Poole (National Institute for Biological Standards and Controls): 'Cytokine Storm in the phase 1 trial of monoclonal antibody TGN1412 better understanding the causes to improve preclinical testing of immunotherapeutics' (16 Dec)
  • Dr Ben Field (Imperial College, London): 'New targets peripheral obesity' (17 Dec)
  • Dr Nick Finer (Wellcome Clinical Research Facility, Cambridge): 'Clinical challenges: can current drugs compete with surgery?' (17 Dec)
  • Dr Christine Mummery (Leiden University Medical Centre, Netherlands): 'Cardiomyocytes from human embryonic stem cells: towards cell-based therapy and disease models' (18 Dec)
  • Dr Marisa Jaconi (Geneva University, Switzerland): ' Tissue-engineered strategies using biomatrices to implant stem cells into the infarcted heart' (18 Dec)
  • Dr Kai C. Wollert (Hanover Medical School, Germany): 'Bone marrow cell therapy after myocardial infarction: the BOOST experience' (18 Dec)


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-771-788-1563
University of Manchester
Source:Eurekalert

Related medicine news :

1. Cancer to Surpass Heart Disease as Worlds Leading Killer
2. Leading U.S. Cancer Organizations Unite Against the Growing Global Cancer Burden
3. Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications
4. Misleading media coverage of medicine
5. Leading German Health Insurance Organization, Deutsche Angestellten-Krankenkasse (DAK), Standardizes on Jive Software to Harness Employee Knowledge
6. Tigermed Forms Strategic Partnerships With Leading CROs in Russia and South Korea
7. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
8. Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign
9. Leading Healthcare Provider Signs Agreement With UCN for inContact
10. Leading Scientists From Around the World Headed to Kansas for Symposium on Combating Deadly Infectious Diseases
11. Caring.com and Alzheimer's Association Use Social Media to Help Spread Awareness for the Nation's Sixth Leading Cause of Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... More ... school and while 84 percent of parents report speaking with their child about sex ... and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its ...
(Date:12/2/2016)... Hawaii (PRWEB) , ... December 02, 2016 , ... ... 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering ... in the field of pain management. , The demand for supplemental training ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a ... No other wearable health technology on the market can deliver all that rejiva can. ... meaningful insights about their health than the usual heart rate and steps taken”, adds ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec 2, 2016 Research and ... Size, Share, Development, Growth and Demand Forecast to 2022" report to ... , , ... of $6 billion in 2015, and it is expected to grow at ... segment is expected to witness faster growth during the forecast period, a ...
(Date:12/2/2016)... CORDOBA, Spain , Dec. 2, 2016 ... additional natural sources apart from those derived from C. ... Córdoba, the Universita` di Napoli Federico II , ... have created the first comprehensive, critical, integrated and unified ... The article focuses on the remarkable chemical ...
(Date:12/2/2016)... Dec. 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), ... Specialties, Inc. ("PSI").  The combination of Texas ... -based PSI bring together both company,s clinical expertise and ... payers an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology: